Healthcare / BiotechnologyNYSE American
$7.80
-0.37 (-4.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-39.4M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$286M
P/E
N/A
•EV/EBITDA
N/A
•ROE
79.5%
↑Gross Margin
N/A
•Debt/Equity
-1.32
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-173.8M · FCF $-26.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Net Income | $-173.8M | $-173.8M | $-18.9M | $-69.0M | $-36.9M | $-23.2M | $-22.2M | $-19.5M | $-16.7M | $-12.8M | $-18.8M | $-516000.00 | $23.1M | $-64.6M |
| EBITDA | $-155.7M | $-155.7M | $-6.8M | $-65.4M | $-36.0M | — | — | — | — | — | — | — | — | — |
| EPS | -4.80 | -4.80 | -0.89 | -1.91 | -1.08 | -0.96 | -1.35 | -2.55 | -3.59 | -30.52 | -345.38 | -278.60 | -326.20 | -4480.00 |
| Balance Sheet | ||||||||||||||
| Debt/Equity | -1.32 | -1.32 | -2.63 | -3.75 | 1.35 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.64 | 0.64 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-26.3M | $-26.3M | $-39.4M | $-55.6M | $-34.7M | $-24.9M | $-19.1M | $-15.8M | $-11.5M | $-9.3M | $-10.9M | — | — | — |
| Returns | ||||||||||||||
| ROE | 79.5% | 79.5% | 39.4% | 215.3% | -102.3% | -91.2% | -117.6% | -133.5% | -217.1% | -52.7% | -193.7% | -4.1% | 672.4% | 285.4% |
| Valuation | ||||||||||||||
| P/B | — | — | — | — | 1.33 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| EPS Growth | -439.3% | -439.3% | 53.4% | -76.9% | — | 28.9% | 47.1% | 29.0% | 88.2% | 91.2% | -24.0% | 14.6% | 92.7% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+300.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.89 → -4.80
Residual
+300.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.